Background Back pain remains a challenge for primary care internationally. One model that has not been tested is stratifi cation of the management according to the patient's prognosis (low, medium, or high risk). We compared the clinical eff ectiveness and cost-eff ectiveness of stratifi ed primary care (intervention) with non-stratifi ed current best practice (control).
Introduction
Back pain remains a major international health problem, with a lifetime prevalence of 80-85% 1 that poses substantial challenges for clinical management. 2 For example, in the UK, each year 6-9% of adults consult their general practitioner about back pain, 3 with only 20-40% no longer reporting pain or disability a year later. 4 Therefore, improvement of the primary care management of low back pain has the potential to reduce the long-term eff ects of back pain, including persistent disabling symptoms, low quality of life, and reduced capacity to work. 5 Results of primary care trials [6] [7] [8] [9] show that more sophisticated treatments (such as manual treatments, exercise, and cognitive behavioural approaches) are more eff ective than usual or minimal care of back pain. However, because of insuffi cient evidence, guideline recommendations 10 are not clear about the clinical selection of patients who are likely to benefi t from additional interventions. Generally, for most patients with non-specifi c back pain, initial referral decisions are based on clinical intuition despite evidence to suggest that this provides ineffi cient and inconsistent access to treatment. 11 The alternative option, referral of all patients with back pain for treatment, is generally thought to be unnecessary, impractical, and ineffi cient because of the high numbers and costs. 5, [10] [11] [12] A one-size-fi ts-all primary care strategy 13 is suboptimum because it ignores the heterogeneity in patients. 14 A novel approach, gaining interest in other medical specialties, 15 but not yet tested in the management of back pain, is to test whether stratifi ed care according to the estimated risk of poor prognosis (defi ned here as persistent disability because of back pain) improves clinical outcomes while remaining cost eff ective. We developed a stratifi ed model of primary care management of back pain, 16 which consists of two complementary components. First, a previously validated, simple-to-use prognostic screening method (the Keele STarT Back Screening Tool), [17] [18] [19] to allocate patients into one of three risk-defi ned groups-low, medium, and high (webappendix p 1). Second, three treatment pathways, developed with clinical experts (webappendix p 2), were matched to these risk groups. 16 In this trial, we test the main hypothesis that a stratifi ed approach to primary care management for low back pain results in clinical and economic benefi ts compared with current best practice. Our other aims were to test See Online for webappendix diff erences within each of the three risk groups-for lowrisk patients, whether minimum treatment provided non-inferior clinical outcomes to current best care; for medium-risk patients, whether systematic referral to physiotherapy led to better clinical outcomes than did current best care; and for high-risk patients, whether systematic referral to psychologically augmented physiotherapy led to better clinical outcomes than did current best care.
Methods Participants
The methods are reported in full in the protocol. 16 In ten general practices within the Keele General Practice Research Partnership, England, adults who had consulted their doctor about back pain during June, 2007, to November, 2008, were identifi ed through weekly searches of electronic patients' records for morbidity codes for back pain. 16 Individuals who were identifi ed were sent a letter from back pain referral services in two National Health Service (NHS) centres, with an invitation to telephone to make an appointment at the initial assessment clinic, information about the trial, and baseline questionnaires. At the clinic, a research nurse assessed patients for eligibility, obtained written informed consent, and checked completion of the questionnaire, including the STarT Back Screening Tool (webappendix p 1). 17 Patients were included in the study if they were at least 18 years old, could speak and understand English, and had back pain of any duration, with or without associated radiculopathy. We excluded patients with potentially serious disorders (eg, cauda equina compression, infl ammatory arthritis, and malignancy), serious illness or comorbidity (including those undergoing treatment for a prevalent axis 1 or 2 mental health disorder according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition [DSM-IV] criteria), who had spinal surgery in the past 6 months, who were pregnant, who were receiving back treatments (except primary care), and who were unable or unwilling to attend (fi gure 1).
A trial steering and independent data monitoring committee oversaw the trial. The North Staff ordshire Local Research Ethics Committee approved the protocol.
Randomisation and masking
A clinic administrator telephoned a remote clinical trials unit (Keele University), which assigned participants to intervention and control groups by use of computergenerated stratifi ed block randomisation (block sizes of three) in a 2:1 ratio to enable future secondary analysis of targeted treatment mechanisms. Stratifi cation was accord ing to the NHS centre (n=2) and STarT Back Screening Tool risk subgroup. Participants, administrator, or physiotherapists could not be masked to randomisation because therapists were administering the active intervention; however, we ensured that the therapists administering the control treatment were not made aware of the details of the stratifi ed model of care during the trial, and that patients were made aware that they would be treated according to one of two primary care management models. The research nurse who retrieved outcome data was masked to randomisation, and the concealment strategies were that the nurse was in a separate offi ce during clinic, the administrator randomly assigned the patients, and the use of a masked follow-up database.
Baseline clinical assessment and treatment
On the same day and in the same NHS centre as the nurse assessment, baseline clinical and treatment sessions were delivered to intervention and control groups by study physiotherapists. To guard against learning and contamination eff ects, diff erent physiotherapists (13 in the intervention group and 40 in the control group) delivered initial clinic and ongoing physiotherapy. Irrespective of the treatment group, participants were not restricted from using health care elsewhere or seeing their general practitioner during the follow-up.
In the control group, during the baseline clinical assessment and treatment session, decisions about referral were made on the basis of the physiotherapists' clinical judgment, without knowledge of a participant's STarT Back Tool classifi cation. Participants received a 30-min physiotherapy assessment and initial treatment including advice and exercises, with the option of onward referral to further physiotherapy. Control physiotherapists received a half day training to familiarise them with study procedures.
In the intervention group, during the baseline clinical assessment and treatment session, decisions about referral were made by use of the STarT Back Screening Tool classifi cation. The 30-min assessment and initial treatment were delivered according to an agreed protocol, with advice focusing on promotion of appropriate levels of activity, including return to work, and a pamphlet about local exercise venues and self-help groups. Participants were shown a 15-min educational video entitled Get Back Active 20 and given the Back Book.
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Low-risk patients were only given this clinic session; medium-risk and high-risk patients were referred for further physiotherapy-led treat ment sessions. Clinic physiotherapists doing the assess ments in the intervention group were given 1 day of training about the STarT Back Screening Tool, and to standardise advice and data gathering from the case report forms.
Follow-up treatment sessions
In the control group, referral for further physio therapy was entirely at the clinical discretion of the physio thera pists delivering the baseline session. The physiotherapists to whom they could refer were in usual NHS practice settings and did not overlap with the physiotherapists providing follow-up sessions in the intervention group. Such physiotherapists have general training in physical therapies and some training in more complex psycho logically
For the STarT Back trial protocol see http://www.ncbi.nlm.nih. gov/pmc/articles/PMC2377248/ pdf/1471-2474-9-58.pdf informed treatments, but none underwent special training or instruction related to this study.
In the intervention group, medium-risk patients, according to the STarT Back Screening Tool, were referred for standardised physiotherapy to address symptoms and function. High-risk patients were referred for psychologically informed physiotherapy to address physical symptoms and function, and also psychosocial obstacles to recovery. Physiotherapists delivering the medium-risk intervention were given 3 days of additional training, and those delivering the high-risk intervention had 6 days of additional training (ie, 9 days in total).
Outcomes
Demographic data and clinical outcomes were gathered before randomisation and 4 months and 12 months later by use of postal questionnaires. Case report forms were used to gather data about treatment content from the physiotherapists. Descriptions and psychometric properties of the secondary outcome measures are reported in detail elsewhere. 16 Secondary outcome measures were referral for further physiotherapy, back pain intensity, the Pain Catastrophizing Scale 23 (measures the extent to which someone has a pessimistic outlook of back pain), fearavoidance beliefs (Tampa Scale of Kinesiophobia 24 ), Hospital Anxiety and Depression Scale, 25 health-related quality of life (EuroQol EQ-5D; 26 Short Form 12 27 physical and mental component scores), STarT Back Screening Tool risk-subgroup reduction, perception of overall change in back pain (global change), number of physiotherapy treatment sessions, attendance at initial physiotherapy treatment, adverse events, health-care resource use and costs over 12 months, number of days off work because of back pain, and satisfaction with care.
We did a telephone follow-up of non-responders at both timepoints for disability, and catastrophising and global changes. Adverse events were defi ned as any serious morbidity or events causing unwarranted distress to a participant that were potentially related to either intervention; information was gathered by the physiotherapists and from patients' self-completed questionnaires.
Statistical analysis
The trial hypotheses were tested by use of pretreatment randomisation allocation to low-risk, medium-risk, and high-risk groups in the intervention and control groups. Since the secondary hypotheses to test diff erences at a risk-group level required a larger sample size than did the primary hypothesis, we used this for our power calculation. Hence, the sample size calculation was based on the ability to detect, for high-risk and medium-risk groups, a between-treatment mean diff erence of 2·5 RMDQ points at the 12-month primary endpoint with a 5% two-tailed signifi cance level; and for the low-risk group, an equivalent one-tailed 2·5% level non-inferiority test. Allowing for a 20% loss to follow-up, we aimed to recruit 800 participants. However, during recruitment, on the basis of the recommendation by our trial data monitoring committee, this number was revised to 850 participants to compensate for a larger than anticipated loss at the 12-month follow-up of 25%. Although powered to detect diff erences in the low-risk, medium-risk, and high-risk groups, the revised total sample size provided 80% power to detect an overall treatment eff ect size of 0·2, equivalent to a mean diff erence in RMDQ scores between the intervention and control groups of about 1.
Analysis was by intention to treat. For the primary analyses, imputed datasets were used for all descriptive and inferential assessments to address attrition bias, generated through multiple imputation (pooled estimates of fi ve imputed datasets) by use of simulation based on a multivariate normal model (numerical variables) and a logistic regression model (categorical outcomes). 28 Estimates of treatment eff ect (mean diff erence for numerical outcomes, odds ratios for categorical outcomes, and incidence rate ratios for lost work days), with 95% CI, were obtained by use of linear, binary logistic, ordinal logistic, and Poisson regression models respectively, with adjustment for baseline score, age, sex, RMDQ, and back pain duration (as agreed a priori with our trial steering group). Standardised eff ect sizes were reported, alongside numbers needed to treat (NNT) by use of at least 30% change in RMDQ; 29 and calculation of 95% CI for NNT by use of Stang and colleagues' recommendations. 30 Sensitivity analyses were done by use of complete-case analysis (ie, non-imputed dataset) and further adjustment for therapist's eff ects with random-eff ects modelling of main therapist. All analyses were done with SPSS (version 17.0.1) and STATA (11.0).
The analysis of cost-eff ectiveness focused on estimation of mean incremental quality-adjusted life years (QALYs) and back-pain-related health-care costs for the overall stratifi ed management approach by use of a within-trial analysis. QALYs were calculated with the EQ-5D. Details of the numbers of physiotherapy sessions attended by each participant were obtained through case report forms and an audit of clinical notes for the participating physiotherapy services. Other health-care costs were estimated from responses to the resource-use items contained within the 12 month self-report questionnaire. Details of the unit costs applied to units of resource use are provided in webappendix p 5. Like the clinical analysis, the economic evaluation was replicated in the complete-case dataset.
To assess the economic consequences of the stratifi ed management intervention beyond health-care resources, costs were also assigned to self-reported work absence by use of the human capital approach; self-reported work absence was weighted by respondent-specifi c wage rates identifi ed from data for yearly earnings and UK Standard Occupational Classifi cation codes. 31, 32 Because of the 12-month follow-up during the study, costs or health benefi ts were not discounted.
This study is registered, number ISRCTN37113406.
Role of the funding source
Keele University sponsored the trial, approved the design, and appointed the trial steering and data monitoring committee. The funder was not involved in the preparation of the study protocol, management of the trial, analysis of the data, or preparation of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication. Figure 1 shows the trial profi le; 851 patients were randomly assigned to the intervention and control groups. In the intervention group, referral decisions were in agreement with those predicated by use of the STarT Back Screening Tool in 553 cases, but not in 15 cases-11 low-risk patients were referred and four medium-risk patients were not referred (fi gure 1). This diff erence arose because therapists were allowed to overrule the STarT Back Screening Tool recommendation if the clinician thought that the decision to overrule was appropriate. Referral patterns were substantially diff erent in controls, with more than a third of medium-risk and high-risk patients not referred for physiotherapy, and about half of all lowrisk patients referred for treatment (fi gure 1). Among the participants referred, initial treatment attendance was 528 (93%) in the intervention group and 263 (93%) in the control group, with those in the intervention group receiving fewer physiotherapy sessions (mean Data are number (%), unless otherwise indicated. RMDQ=Roland and Morris Disability Questionnaire. *Mean for the intervention group minus mean for the control group (by use of linear regression adjusted for age, sex, baseline RMDQ, and duration of back pain). †Based on observed or available case data. ‡Based on imputed datasets with adjustment for clustering by therapist (by use of random-eff ects linear regression modelling). §Mean diff erence relative to the pooled SD of baseline scores. ¶Defi ned as at least 30% change in the RMDQ score compared with baseline; the numbers represent average rounded counts of fi ve imputed datasets. ||Odds of a good outcome in the intervention group relative to the control group (by use of binary logistic regression with adjustment for age, sex, baseline RMDQ, and duration of back pain). **Based on the point estimate for the proportion of patients with good outcomes in the control group and the odds ratio for good outcomes in the intervention group relative to the control group; smaller positive numbers for the 95% CI convey a stronger association than do larger positive numbers and smaller negative numbers indicate a greater advantage towards the control group, and therefore the number needed to treat does not necessarily lie within the 95% CI. the between-group adjusted mean diff erences in change in RMDQ scores were signifi cant at 4 months and 12 months, equating to standardised eff ect sizes of 0·32 and 0·19, respectively (table 2) . Diff erences in secondary outcome measures in favour of the intervention for all participants were signifi cant at 4 months for pain intensity, catastrophising, fear, anxiety, depression, general health (physical component), STarT Back Screening Tool risk reduction, and global change (table 3); and at 12 months for catastrophising, fear, depression, general health (physical component), and risk reduction (table 3) . The patients in the intervention group were signifi cantly more likely to be satisfi ed with treatment (data available for 4 months follow-up), and took fewer days off work because of back pain (data available for 12 months follow-up).
Results
Details of health-care resource use, health-care costs, days off work, and health-related quality of life (EQ-5D scores and QALY estimates) are provided in webappendix p 7 for each group. The stratifi ed management intervention resulted in greater mean health benefi t (0·039 additional QALYs), achieved at a lower mean health-care cost (cost saving £34·39; webappendix p 8), than the control. Similar inferences were drawn from the complete-case analysis (0·033 additional QALYs and a mean cost saving of £41·93; webappendix p 8). Figure 3 shows the cost-eff ectiveness plane for the primary analysis, generated from 25 000 bootstrap samples. 16 The dominance of the stratifi ed intervention (ie, greater benefi t at lower cost) was shown in 92% of replications (ie, 92% of bootstrapped cost-eff ect pairs were in the southeast quadrant).
The societal benefi t from fewer work days lost because of back pain corresponded to a mean indirect (productivity) cost saving of £675 over the 12-month follow-up for the intervention group compared with the control group (webappendix p 8).
For the primary and secondary clinical outcomes, diff erences between the intervention and control groups within the low-risk group indicated non-inferiority, although signifi cantly fewer work days were lost in the intervention group (table 2, table 3 ). For the medium-risk and high-risk groups, the adjusted between-group mean diff erences in RMDQ scores were signifi cant at 4 months (table 2), but the diff erence was only signifi cant for the medium-risk group and not the high-risk group at 12 months (table 2). One notable fi nding was that the mean number of work days lost at 12 months was far fewer in the medium-risk participants in the intervention group than in the control group. 
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Discussion
A stratifi ed management approach in which prognostic screening and treatment targeting were combined resulted in improved primary care effi ciency, leading to higher health gains for patients with back pain than did existing non-stratifi ed best care. Signifi cant improvements were not only noted in the primary outcome measure (disability) at both 4-month and 12-month follow-ups, but also for a range of secondary outcome measures, including physical and emotional functioning, pain intensity, quality of life, days off work, global improvement ratings, and treatment satisfaction. Although the eff ect sizes for the targeted intervention were similar to other primary care trials, 6-9 the additional benefi t provided by stratifi ed care is noteworthy when the size of the disability reduction in the control group is considered. Mean RMDQ change scores in the control group were larger at 4 months and 12 months than the within-group change of 2·5 points generally judged to be a clinically meaningful change, 34 and also larger than reductions noted in the active intervention groups of other trials (panel). 6, 7, 9 From an economics perspective, the stratifi ed management approach was associated with improvements in health-related quality of life (QALYs), a reduction in health-care use, and fewer days off work related to back pain. Health benefi ts and cost savings attributable to the stratifi ed intervention might have been underestimated; resource use outside the study clinic sessions was less common and the between-group diff erence in quality of . †Odds ratio represents the proportional odds in terms of ordered response categories for the intervention group relative to the control group (by use of ordinal logistic regression adjusted for age, sex, baseline RMDQ, and duration of back pain). ‡Analysis of time off work (days) is based on a total subsample of 298 of 567 responders who reported being currently employed at 12 months follow-up, and relates to leave due to low back pain during the period between baseline and follow-up at 12 months. §Incidence rate ratio for the extra work days lost in the control group relative to the intervention group (by use of Poisson regression adjusted for age, sex, baseline RMDQ, and duration of back pain). ¶Analysis was based on 613 responders to the question about satisfaction with care at 4 months follow-up: 416 in the intervention group and 197 in the control group. life was greater at 12 months than at 4 months. The potential for long-term economic benefi ts lends further support that a stratifi ed management approach provides value for money. Use of the screening method resulted in important diff erences in the pattern of treatment referral between the groups. Outcomes in the low-risk group were non-inferior despite far less low-risk intervention patients (7%) having a referral for further treatment than the lowrisk controls (49%) referred for an average of fi ve physiotherapy sessions. This fi nding was in keeping with our theory that a substantial proportion of referrals based on clinical judgement alone (controls) might be unnecessary and that many low-risk patients are receiving unnecessary treatment in current practice. 35 By contrast, 113 (40%) medium-risk and 91 (32%) high-risk patients in the control group were not off ered further treatments, which is likely to have contributed to their signifi cantly smaller reductions in disability than in the medium-risk and high-risk patients in the intervention group at 4 months and 12 months. Our interpretation of these fi ndings is that, without systematic prognostic screening to assist treatment referral, many medium-risk and highrisk patients are potentially being denied access to more sophisticated treatments that are likely to improve their clinical outcomes. This issue is perhaps most important for patients classifi ed as high risk (28%) who showed signifi cant, substantial reductions in disability (RMDQ) at 4 months (mean change 6·8; table 2). Although these results lend some support to the use of psychologically informed physiotherapy for patients with psychological distress, 7 further research is needed to establish if these short-term benefi ts can be sustained, because the diff erence between the high-risk groups at 12 months (5·9) was not signifi cant. Noteworthy is that, with the design used for this pragmatic clinical trial, we are not able to ascertain whether risk-group level benefi ts were the result of improvements in referral patterns, or to improvements in the content or quality of the follow-up physiotherapy sessions. Nevertheless, our fi ndings support the clinical eff ectiveness and cost-eff ectiveness of a combined stratifi ed management approach.
The strengths of this trial include high internal validity, with remote randomisation, treatments delivered according to protocols, eff ective masking of assessors, consistent fi ndings for several disparate outcomes, and a sample size large enough to enable a separate examination of the eff ectiveness within the low-risk, medium-risk, and high-risk groups. Another strength is that the sensitivity analyses, including a conservative approach with adjust ment for any potentially unequal therapist expertise or skills (therapist eff ects), 36 did not change the clinical or economic fi ndings. Limitations included a greater than anticipated loss to follow-up and a slight imbalance in attrition between the groups, addressed through extended recruitment and imputation. Also because delivery of physiotherapy was complex, with a variable number of sessions by a variable number of diff erent physiotherapists, the random-eff ect adjustment for the therapist could only be applied in the adjustment for diff erences with a designated main therapist. Additional between-group variability might have remained unadjusted.
The wider implications of the results of this trial are that patients' outcomes can be improved with a stratifi ed approach to primary care management of low back pain. Results from primary care cohort studies 18 suggest that the low-risk group might represent as many as 56% of all back pain consultations with the family doctor. Hence, substantial reductions could have occurred in health-care use and time off work if stratifi ed primary care were implemented. We recognise the challenges in implementing these fi ndings in clinical services, and that our results might not be generalisable to other health-care settings or musculoskeletal complaints. Our research group and others are investigating implementing stratifi ed management into routine primary care in the
Panel: Research in context
Systematic review Previous reports of relevant large randomised controlled trials, international guidelines, and meeting abstracts were searched with Ovid Medline up to May, 2011, using exploded Medline Medical Subject Headings and free text terms for "back pain" in combination with "primary health care". This search was restricted to English language papers and the few Medline clinical queries were used to restrict the search to studies of treatments only (to achieve maximum specifi city). The evidence suggests that sophisticated treatments (such as manual treatments and exercise) are more eff ective than are minimal packages of care but similar to each other. 10 There are no trials of methods for tailoring treatment to individual patients or investigation of the clinical eff ectiveness and cost-eff ectiveness of using prognostic screening protocols to help identify patients to be targeted with referral beyond minimum treatment.
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Interpretation
This trial is unique in that the results show the role of system-wide changes with a stratifi ed approach to improve outcomes in patients with low back pain and reduce health-care costs. Although the eff ect sizes were similar to those of other trials, [6] [7] [8] [9] these improvements are noteworthy because improvements in the control group were substantial and similar to those of the active interventions in other clinical trials;
6-9 the control included sophisticated treatments, not just minimum care; and the stratifi ed intervention was highly cost eff ective. Although referral rates with stratifi ed management were higher, these health-sector costs were outweighed by savings due to reductions in referral of low-risk patients and overall use of health-care resources during the follow-up. The results of this trial have important implications for commissioners and providers of services for back pain.
UK, 37 with further collaborative research in the USA, Denmark, and the Netherlands.
For many years, the potential for targeting treatment has been emphasised as a research priority for back pain. 38 The results of this trial provide the fi rst evidence that a stratifi ed management approach to target the provision of primary care signifi cantly improves patient outcomes and is associated with substantial economic benefi ts compared with current best practice. As such, the fi ndings of this study represent an important advance in primary care management of back pain, and have important implications for commissioners and providers of services for back pain.
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